How is METHYLOMIC funded?

The project has received funding from the European Union’s Horizon Europe programme under grant agreement No 101095449

“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.”

Funding programme: Horizon Europe Framework Programme (HORIZON)

Cluster 1: HEALTH

Destination: Unlocking the full potential of new tools, technologies and digital solutions for a healthy society:

Technology is a key driver for innovation in the health care sector. It can provide better and more cost-efficient solutions with high societal impact, tailored to the specific health care needs of the individual. However, novel tools, therapies, technologies and digital approaches face specific barriers and hurdles in piloting, implementing and scaling-up before reaching the patient, encountering additional challenges such as public acceptance and trust. Emerging and disruptive technologies offer big opportunities for transforming health care, thereby promoting the health and well-being of citizens. Unlocking this potential and harnessing the opportunities depends on the capacity to collect, integrate and interpret large amounts of data, as well as ensure compatibility with appropriate regulatory frameworks and infrastructures that will both safeguard the rights of the individual and of society and stimulate innovation to develop impactful solutions.

Call: Tools and technologies for a healthy society (Single Stage – 2022) (HORIZON-HLTH-2022-TOOL-11)

Topic title: Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers

The specific HORIZON-HLTH-2022-TOOL-11-01 funding call